Phase 2 Clinical Data Highlights: Hemab's Phase 2 study of sutacimig (N=34) is intended to address a profound gap in care for GT as there are currently no effective prophylactic treatment options.

(51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit- At year five, mean ...

The December issue of the Journal of Cardiac Failure (JCF), now available, offers a robust lineup of original research, ...

HYMPAVZI is currently approved in more than 40 countries for the treatment of eligible patients 12 years of age and older living with hemophilia A without factor VIII inhibitors, or hemophilia B ...

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo ...

Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data ...

Strong positive results of a novel combination of two immunotherapy drugs as a treatment for multiple myeloma after other treatments have failed suggest the combination could be a “functional cure,” ...

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...

Decreases in hereditary angioedema attack rates seen with daily oral deucrictibant at 13 weeks stayed at a low level for up to 34 months, according to open-label extension study results.These data on ...

At some point during 2 years of chemotherapy, 30% of families reported household material hardship and 31.5% had income loss ...

Among adults with hereditary angioedema, a one-time infusion of lonvoguran ziclumeran immediately lowered the average monthly ...

Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be self-administered by patients every four or eight weeks. The first-in-class drug targets ...